1. Search Result
Search Result
Results for "

adjunct

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

1

Peptides

1

Inhibitory Antibodies

2

Natural
Products

5

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-A0166
    Cilastatin
    2 Publications Verification

    MK0791

    Bacterial Antibiotic Infection
    Cilastatin (MK0791) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC50 of 0.1 μM. Cilastatin inhibits the bacterial metallob-lactamase enzyme CphA with an IC50 of 178 μM. Cilastatin is an antibacterial adjunct .
    Cilastatin
  • HY-A0166A
    Cilastatin sodium
    2 Publications Verification

    MK0791 sodium

    Bacterial Antibiotic Infection
    Cilastatin sodium (MK0791 sodium) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC50 of 0.1 μM. Cilastatin sodium inhibits the bacterial metallob-lactamase enzyme CphA with an IC50 of 178 μM. Cilastatin sodium is an antibacterial adjunct .
    Cilastatin sodium
  • HY-114703
    Eslicarbazepine
    1 Publications Verification

    BIA 2-194

    Beta-secretase Sodium Channel Neurological Disease
    Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.
    Eslicarbazepine
  • HY-B2156

    Vitamin K2(MK-4); Menaquinone K4

    Endogenous Metabolite Cancer
    Menaquinone-4 is a vitamin K, used as a hemostatic agent, and also a adjunctive therapy for the pain of osteoporosis.
    Menaquinone-4
  • HY-A0166R

    Infection
    Cilastatin (Standard) is the analytical standard of Cilastatin. This product is intended for research and analytical applications. Cilastatin (MK0791) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC50 of 0.1 μM. Cilastatin inhibits the bacterial metallob-lactamase enzyme CphA with an IC50 of 178 μM. Cilastatin is an antibacterial adjunct .
    Cilastatin (Standard)
  • HY-A0166S

    MK0791-15N,d3

    Bacterial Antibiotic Infection
    Cilastatin- 15N,d3 is a 15N-labeled and deuterium labeled Cilastatin. Cilastatin (MK0791) is a reversible, competitive renal dehydropeptidase I inhibitor with an IC50 of 0.1 μM. Cilastatin inhibits the bacterial metallob-lactamase enzyme CphA with an IC50 of 178 μM. Cilastatin is an antibacterial adjunct[1][2][3].
    Cilastatin-15N,d3
  • HY-B1475

    Octatropine bromide

    mAChR Neurological Disease Metabolic Disease
    Anisotropine (Octatropine) bromide is an orally active anticholinergic muscarinic antagonist. Anisotropine bromide can inhibit gastric acid secretion and is used as an adjunct to peptic ulcers .
    Anisotropine bromide
  • HY-A0042

    CGP 33101; E 2080; RUF 331

    Others Neurological Disease
    Rufinamide(E 2080; CGP 33101; RUF 331) is a new antiepileptic agent that differs structurally from other antiepileptic drugs and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS).
    Rufinamide
  • HY-B2156S1

    Vitamin K2(MK-4)-13C6; Menaquinone K4-13C6

    Isotope-Labeled Compounds Endogenous Metabolite Cancer
    Menaquinone-4- 13C6 is the 13C-labeled Menaquinone-4. Menaquinone-4 is a vitamin K, used as a hemostatic agent, and also a adjunctive therapy for the pain of osteoporosis.
    Menaquinone-4-13C6
  • HY-106450

    MRE-0470; WRC 0470

    Adenosine Receptor Cardiovascular Disease
    Binodenoson (MRE-0470) is a potent and selective A2A adenosine receptor agonist (KD=270 nM). Binodenoson is being developed as a short-acting coronary vasodilator as an adjunct to radiotracers for use in myocardial stress imaging .
    Binodenoson
  • HY-147263

    CC-11050

    Phosphodiesterase (PDE) Infection Inflammation/Immunology
    Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor and can reduce the inflammatory response and improves Isoniazid (INH)-mediated bacillary clearance from the lungs. Dovramilast, as an adjunct, is used for the research of tuberculosis (TB) .
    Dovramilast
  • HY-A0042S

    CGP 33101-d2; E 2080-d2; RUF 331-d2

    Isotope-Labeled Compounds Neurological Disease
    Rufinamide-d2 (CGP 33101-d2) is the deuterium labeled Rufinamide. Rufinamide (E 2080) is a new antiepileptic agent that differs structurally from other antiepileptic drugs and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS).
    Rufinamide-d2
  • HY-14263

    Propericiazine; RP 8909

    Dopamine Receptor Neurological Disease
    Pericyazine (Propericiazine) is a first-generation antipsychotic agent that is used as an adjunct to the short-term management of severe anxiety states and psychosis . Pericyazine is a selective D2-dopamine receptor antagonist . Pericyazine has adrenolytic, anticholinergic, and extrapyramidal effects .
    Pericyazine
  • HY-A0042S1

    CGP 33101-15N,d2; E 2080-15N,d2; RUF 331-15N,d2

    Isotope-Labeled Compounds Neurological Disease
    Rufinamide- 15N,d2 is the deuterium and 15N labeled Rufinamide[1]. Rufinamide is a new antiepileptic agent that differs structurally from other antiepileptic agents and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS)[2][3].
    Rufinamide-15N,d2
  • HY-B2156S

    Vitamin K2(MK-4)-d7; Menaquinone K4-d7

    Endogenous Metabolite Cancer
    Menaquinone-4-d7 (Vitamin K2(MK-4)-d7) is the deuterium labeled Menaquinone-4. Menaquinone-4 is a vitamin K, used as a hemostatic agent, and also a adjunctive therapy for the pain of osteoporosis.
    Menaquinone-4-d7
  • HY-A0248
    Polymyxin B Sulfate
    Maximum Cited Publications
    6 Publications Verification

    Bacterial Antibiotic Infection
    Polymyxin B Sulfate is a potent antibacterial agent and a relatively toxic antibiotic. Polymyxin B Sulfate also is a antiendotoxin agent. Polymyxin B Sulfate shows endotoxin-neutralizing properties can be used as adjunctive research in gram-negative sepsis. Polymyxin B Sulfate shows antibacterial activities in vitro and in vivo .
    Polymyxin B Sulfate
  • HY-P99551

    KBSA301; AR-301

    Antibiotic Infection
    Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent .
    Tosatoxumab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: